Lung Cancer News and Research

Latest Lung Cancer News and Research

Enrollment complete in Cerulean CRLX101 Phase 2 study for non-small cell lung cancer

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC). The company also announced that it has dosed the first patient in a second tumor type.

2 Jul 2012

CytRx granted European patent for tumor-targeting linker platform technology

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that the European Patent Office (EPO) has issued a patent covering the Company's tumor-targeting linker platform technology and pharmaceutical compositions.

2 Jul 2012

Blocking AXL protein may prevent resistance to lung cancer drug

People with lung cancer who are treated with the drug Tarceva face a daunting uncertainty: although their tumors may initially shrink, it's not a question of whether their cancer will return—it's a question of when. And for far too many, it happens far too soon.

2 Jul 2012

Study details canonical Wnt signaling pathway

Many lung cancers are driven by mutations in the epidermal growth-factor receptor (EGFR), and so it makes sense that many successful modern treatments block EGFR activity. Unfortunately, cancers inevitably evolve around EGFR inhibition, and patients with lung cancers eventually relapse.

30 Jun 2012

Pregnant women with preeclampsia, diabetes need biomarkers checked

Researchers are calling for cardiovascular biomarker profiling in pregnant women with preeclampsia and diabetes to help predict their future CV disease risk.

29 Jun 2012

$Epilepsy patients unaware of fracture risk$

Epilepsy patients unaware of fracture risk

Few patients with epilepsy are aware that taking anti-epileptic drugs puts them at increased risk for falls and fractures, report researchers.

29 Jun 2012

Young inflammatory bowel disease patients have low bone mass

Children and adolescents with inflammatory bowel disease have significantly lower bone mineral density than their healthy peers, even after adjusting for pubertal delay, Finnish researchers report.

29 Jun 2012

Recurring diabetic foot ulcers ‘predictable’

The risk for recurring diabetic foot ulcers is predicted by clinical characteristics, such as existing ulcer location, bone infection, and diabetes control, demonstrates research published in International Wound Journal.

29 Jun 2012

ACR updates 39 appropriateness criteria topics and adds five new criteria

New and updated evidence-based guidelines to help health care providers choose the most appropriate medical imaging exam or radiation therapy for a patient's clinical condition are now available via the latest version of the American College of Radiology (ACR) Appropriateness Criteria.

29 Jun 2012

Statins for erectile dysfunction proposed

Family doctors should offer men with erectile dysfunction treatment with a statin – not only to improve their quality of life but also to reduce their future cardiovascular risk.

28 Jun 2012

Why our eyes are bigger than our stomachs

Viewing images of high-calorie foods can trigger hunger cravings, suggests research presented at the Endocrinology Society’s annual meeting ENDO 2012 in Houston, Texas, USA.

28 Jun 2012

Detailed study on how diesel soot gets stuck in the lungs

The exhaust from diesel-fuelled vehicles, wood fires and coal-driven power stations contains small particles of soot that flow out into the atmosphere. The soot is a scourge for the climate but also for human health. Now for the first time, researchers have studied in detail how diesel soot gets stuck in the lungs. The results show that more than half of all inhaled soot particles remain in the body.

28 Jun 2012

Second potential immune checkpoint target for cancer immunotherapy announced by Compugen

Compugen Ltd. (NASDAQ: CGEN) announced today results demonstrating the therapeutic potential of CGEN-15022, a Compugen-discovered B7/CD28-like membrane protein, as an immune checkpoint target for treatment of multiple cancers.

27 Jun 2012

Sunshine Biopharma completes Adva-27a cytotoxicity study on multidrug-resistant lung cancer

Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a cytotoxicity study of its lead compound, Adva-27a, in H69AR, a Multidrug Resistant Small Cell Lung Cancer cell line. Cytotoxicity studies measure the ability of a drug to destroy cancer cells in vitro.

27 Jun 2012

New FIRS data reveals lack of understanding and concern among public about lung disease

New data released by the Forum of International Respiratory Societies (FIRS) to coincide with World Spirometry Day today has revealed a lack of understanding and concern among the public about the world's biggest killer - lung disease, which now claims the lives of almost 4 million people a year.

27 Jun 2012

Nanoparticles that can slip through mucus barriers shown to protect against herpes infections

Johns Hopkins researchers say they have demonstrated, for the first time in animals, that nanoparticles can slip through mucus to deliver drugs directly to tissue surfaces in need of protection. The researchers used these mucus-penetrating particles (MPPs) to protect against vaginal herpes infections in mice and the goal is to create similar MPPs to deliver drugs that protect humans against sexually transmitted diseases or even treat cancer.

26 Jun 2012

Experimental medication increases muscle strength in cancer patients with low testosterone levels

An experimental medication safely increases muscle strength and physical functioning among cancer patients with low testosterone levels, a new drug study finds. The results will be presented Sunday at The Endocrine Society's 94th Annual Meeting in Houston.

26 Jun 2012

CytRx achieves key milestone in advancing tamibarotene Phase 2b trial for NSCLC

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the recommendation by the Data Safety Monitoring Board (DSMB) to continue with the global Phase 2b clinical trial with tamibarotene in combination with chemotherapeutical agents as a first-line treatment for patients with advanced non-small-cell lung cancer.

26 Jun 2012

Afirma gene expression test can reduce unnecessary thyroid cancer surgeries

Veracyte, Inc., a molecular diagnostics company that is pioneering the emerging field of molecular cytology, today announced results from a large, prospective, multicenter study, which demonstrated the potential for the Afirma® Gene Expression Classifier, a gene expression test, to reduce the large number of unnecessary surgeries in thyroid cancer diagnosis by more than half.

25 Jun 2012

Riverain's ClearRead Bone Suppression software improves detection of lung cancer

Software by Riverain Technologies significantly improves radiologists' ability to detect potentially cancerous lung nodules in X-ray images, and might be a cost-effective alternative to dual energy subtraction (DES) imaging, according to two new studies being presented at the 20th Anniversary Meeting of the European Society of Thoracic Imaging (ESTI), June 22-24, in London.

23 Jun 2012